Literature DB >> 10864483

The role of nitric oxide, K(+)(ATP) channels, and cGMP in the preconditioning response of the rabbit.

H Horimoto1, G R Gaudette, A E Saltman, I B Krukenkamp.   

Abstract

BACKGROUND: The role of nitric oxide (NO), K(+)(ATP) channels, and cyclic GMP (cGMP) in preconditioning is unknown.
MATERIAL AND METHODS: Isolated rabbit hearts were pretreated with the NO precursor L-arginine (L-Arg), both alone and after infusion of the NO synthetase inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME). Guanylate cyclase inhibitor methylene blue (MB) was infused prior to L-Arg in a separate group of hearts. To contrast the mechanisms of NO preconditioning and potassium channel opener (PCO) preconditioning, we infused the PCO pinacidil after L-NAME and the PCO blocker glibenclamide before L-Arg. Control hearts had no drug infused. The LAD coronary artery was occluded for 1 h and reperfused for 1 h in all hearts. Action potential duration (APD(50)), coronary flow (CF), and left ventricular developed pressure (DP) were measured, and infarct size (IS) was determined and expressed as a percentage of the area at risk.
RESULTS: L-Arg prolonged APD(50) at 60 min of reperfusion (94 +/- 6 ms vs 69 +/- 2 ms (control) vs 70 +/- 2 ms (L-NAME) vs 74 +/- 3 ms (MB), P < 0.05). L-Arg reduced IS compared with control (24 +/- 2% vs 49 +/- 3%, P < 0.05); this was reversed by either L-NAME (53 +/- 4%, P < 0.05) or MB (43 +/- 3%, P < 0.05), but not by glibenclamide (20 +/- 4%), unlike the increase in CF during L-Arg infusion, which was blocked by glibenclamide. Pinacidil infusion decreased IS (26 +/- 2%), but this effect was blocked by L-NAME (53 +/- 7%, P < 0.05 vs pinacidil), although L-NAME did not blunt the increase in CF. There were no significant differences in DP among groups.
CONCLUSION: L-Arginine preconditions the heart through NO generation, and this response is mediated through a cGMP-dependent mechanism, but is independent of the K(+)(ATP) channels. Coronary vasodilation is mediated through a mechanism different from that responsible for cardiomyocyte preconditioning. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10864483     DOI: 10.1006/jsre.2000.5845

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  7 in total

1.  Relationship between basal nitric oxide and ventricular repolarization in an intact heart.

Authors:  Lexin Wang
Journal:  Exp Clin Cardiol       Date:  2003

2.  Nitric Oxide Treatment for Lungs and Beyond. Novel Insights from Recent Literature.

Authors:  Francesco Zadek; Stefano Spina; Jie Hu; Lorenzo Berra
Journal:  Am J Respir Crit Care Med       Date:  2019-09-01       Impact factor: 21.405

3.  The role of mitochondrial K(ATP) channels in antiarrhythmic effects of ischaemic preconditioning in dogs.

Authors:  Agnes Végh; James R Parratt
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

4.  Preischemic infusion of alpha-human atrial natriuretic peptide elicits myoprotective effects against ischemia reperfusion in isolated rat hearts.

Authors:  Hirohisa Okawa; Hitoshi Horimoto; Shigetoshi Mieno; Yukiya Nomura; Masataka Yoshida; Sasaki Shinjiro
Journal:  Mol Cell Biochem       Date:  2003-06       Impact factor: 3.396

Review 5.  Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling.

Authors:  D S Burley; P Ferdinandy; G F Baxter
Journal:  Br J Pharmacol       Date:  2007-08-13       Impact factor: 8.739

6.  The effect of chronic nitric oxide synthases inhibition on regulatory proteins in rat hearts.

Authors:  Anna Spániková; Petra Simoncíková; Tána Ravingerová; Olga Pechánová; Miroslav Barancík
Journal:  Mol Cell Biochem       Date:  2008-03-10       Impact factor: 3.396

7.  The effect of IPC on central and peripheral fatiguing mechanisms in humans following maximal single limb isokinetic exercise.

Authors:  Samuel L Halley; Paul Marshall; Jason C Siegler
Journal:  Physiol Rep       Date:  2019-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.